Table 2.
FibroScan and FibroSure* for diagnosis of cirrhosis
| FibroScan | FibroSure | |
|---|---|---|
| AUROC, mean (95% CI) | 0.94 (0.93–0.95) 41 | 0.86 (0.71–0.92) 38 |
| Sensitivity (95% CI) | 0.83 (0.79–0.86) 104 | 0.85 38 |
| Specificity (95% CI) | 0.89 (0.87–0.91) 104 | 0.81 38 |
| Advantages | Evaluates a genuine property of the liver | Good reproducibility |
| High performance for cirrhosis | High applicability (>95%) | |
| User-friendly, point-of-contact test | ||
| Good reproducibility | ||
| Disadvantages | Decreased performance in obese patients | Nonspecific of the liver |
| Applicability lower than serum biomarkers: failure in 3% of cases and unreliable results in 16% (obesity, ascites, limited operator experience) | ||
| Requires a dedicated device | ||
| Inflammation, extra-hepatic cholestatis, and right heart failure can provide false positive results |
*
Known as FibroTest in Europe.